{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fasting&page=29",
    "query": {
      "intervention": "Fasting",
      "page": 29
    },
    "page_size": 10
  },
  "pagination": {
    "page": 29,
    "page_size": 10,
    "total_count": 2245,
    "total_pages": 225,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fasting&page=30&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fasting&page=28&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T22:00:25.357Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02084875",
      "title": "A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "tofacitinib modified-release (MR) formulation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-04-11",
      "completion_date": "2014-05-25",
      "has_results": false,
      "last_update_posted_date": "2018-11-30",
      "last_synced_at": "2026-10-19T22:00:25.357Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02084875"
    },
    {
      "nct_id": "NCT06609512",
      "title": "A Clinical Study of Enlicitide and the Effect of Food in Healthy Adult Participants (MK-0616-033)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Enlicitide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2024-10-21",
      "completion_date": "2025-01-31",
      "has_results": false,
      "last_update_posted_date": "2025-02-07",
      "last_synced_at": "2026-10-19T22:00:25.357Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06609512"
    },
    {
      "nct_id": "NCT00402909",
      "title": "Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Nateglinide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "78 Years",
        "sex": "ALL",
        "summary": "18 Years to 78 Years"
      },
      "enrollment_count": 28,
      "start_date": "2006-11",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2017-02-24",
      "last_synced_at": "2026-10-19T22:00:25.357Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00402909"
    },
    {
      "nct_id": "NCT00202033",
      "title": "Impact of Self-Monitoring Blood Glucose Frequency on Glycemic Control in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "frequency of self monitoring blood glucose",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "HealthPartners Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 150,
      "start_date": "2004-09",
      "completion_date": "2009-05",
      "has_results": false,
      "last_update_posted_date": "2015-12-03",
      "last_synced_at": "2026-10-19T22:00:25.357Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00202033"
    },
    {
      "nct_id": "NCT05738850",
      "title": "Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Generalized Anxiety Disorder (GAD)",
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "ABBV-932",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 104,
      "start_date": "2023-02-15",
      "completion_date": "2024-05-31",
      "has_results": false,
      "last_update_posted_date": "2024-07-01",
      "last_synced_at": "2026-10-19T22:00:25.357Z",
      "location_count": 2,
      "location_summary": "Anaheim, California • Grayslake, Illinois",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Grayslake",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05738850"
    },
    {
      "nct_id": "NCT03511846",
      "title": "Pain Biomarker Study",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Migraine",
        "Cluster Headache",
        "Trigeminal Autonomic Cephalgia",
        "Hemicrania Continua",
        "Paroxysmal Hemicrania",
        "SUNCT",
        "Short-Lasting Unilateral Neuralgiform Headache With Conjunctival Injection and Tearing"
      ],
      "interventions": [
        {
          "name": "Oral capsaicin",
          "type": "DRUG"
        },
        {
          "name": "Topical capsaicin",
          "type": "DRUG"
        },
        {
          "name": "Intranasal capsaicin",
          "type": "DRUG"
        },
        {
          "name": "Cold Water Irrigation",
          "type": "OTHER"
        },
        {
          "name": "Medical Air",
          "type": "OTHER"
        },
        {
          "name": "Low Flow Oxygen",
          "type": "DRUG"
        },
        {
          "name": "High Flow Oxygen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 371,
      "start_date": "2018-03-21",
      "completion_date": "2028-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-18",
      "last_synced_at": "2026-10-19T22:00:25.357Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03511846"
    },
    {
      "nct_id": "NCT00648193",
      "title": "Fasting Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Paroxetine hydrochloride 40 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "Paxil® 40 mg Table",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2006-12",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-10-19T22:00:25.357Z",
      "location_count": 1,
      "location_summary": "Saint Charles, Missouri",
      "locations": [
        {
          "city": "Saint Charles",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00648193"
    },
    {
      "nct_id": "NCT00867685",
      "title": "Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "AZD2624",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2009-03",
      "completion_date": "2009-04",
      "has_results": false,
      "last_update_posted_date": "2009-04-30",
      "last_synced_at": "2026-10-19T22:00:25.357Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00867685"
    },
    {
      "nct_id": "NCT00778024",
      "title": "Bioequivalence Study of Fluoxetine HCL 40 mg Capsules Under Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "fluoxetine HCL 40 mg capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ranbaxy Laboratories Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2003-08",
      "completion_date": "2003-12",
      "has_results": false,
      "last_update_posted_date": "2009-12-15",
      "last_synced_at": "2026-10-19T22:00:25.357Z",
      "location_count": 1,
      "location_summary": "Saint Charles, Missouri",
      "locations": [
        {
          "city": "Saint Charles",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00778024"
    },
    {
      "nct_id": "NCT04447820",
      "title": "Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IR",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "K-877-ER (Dose A)",
          "type": "DRUG"
        },
        {
          "name": "K-877-ER (Dose B)",
          "type": "DRUG"
        },
        {
          "name": "K-877-IR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kowa Research Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2020-06-10",
      "completion_date": "2020-12-03",
      "has_results": true,
      "last_update_posted_date": "2023-12-22",
      "last_synced_at": "2026-10-19T22:00:25.357Z",
      "location_count": 12,
      "location_summary": "Anniston, Alabama • Jacksonville, Florida • Port Orange, Florida + 9 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04447820"
    }
  ]
}